Neola Medical At Biostock Life Science Fall Summit 2022 The 30th of november, at 11.05am cet, neola medical’s ceo hanna sjöström presents the company and the latest developments at biostock life science fall summit. For the fifth year, we invited you to the biostock life science summit and now you can see all the features here! on november 29 30, over 40 companies in a wide range of therapeutic areas presented their projects and innovations.
Interview With Neola Medical At Nlsdays 2022 Last week, 29–30 november, neola medical attended biostock life science fall summit at medicon village in lund. during the event, ceo hanna sjöström presented the company, the latest development, and upcoming milestones. Neola medical’s presentation at biostock life science fall summit 2022 is now available! 👶🏻🫁 last week, 29–30 november, neola medical attended biostock life science. The summit program features showcases from more than 40 private and listed life science companies. the program will also provide crucial insights into life science investments, capital raising, and market trends, with an exclusive focus on the nordic ecosystem. This year, we will meet in person, as more than 30 listed and private companies from a wide range of therapeutic areas present their innovations and business cases to invited investors. the programme also includes insights from professional investors and sector experts.
Neola Medical Presents At Abgsc S Life Science Summit The summit program features showcases from more than 40 private and listed life science companies. the program will also provide crucial insights into life science investments, capital raising, and market trends, with an exclusive focus on the nordic ecosystem. This year, we will meet in person, as more than 30 listed and private companies from a wide range of therapeutic areas present their innovations and business cases to invited investors. the programme also includes insights from professional investors and sector experts. Oct 11, 2022 2022 cell & gene meeting on the mesa, carlsbad, october 11 13 – oct 6, 2022 icrs focus meeting, bologna, october 6 7 – sep 28, 2022 nordic life science days, malmö, september 28 29, 2022 – aug 30, 2022 2nd integrin targeted drug development summit, boston, august 30 september 1 – jun 13, 2022 småbolagsdagarna, stockholm. We proudly welcome you to the 5th annual fall edition of the biostock life science summit at medicon village in lund on november 29 30! this year, we will meet in person, as around 30 listed and private companies from a wide range of therapeutic areas present their innovations and business cases to invited investors. Lund based neola medical can look back on an eventful period when reporting the third quarter of 2022. positive study results and a successful capital raise provide a stable foundation for the future, where the focus will be on the regulatory work ahead of the market launch. Patients receiving the combination therapy demonstrated a higher tumor response rate and longer progression free survival compared to those receiving chemotherapy alone. moreover, the combination therapy also led to a promising overall survival rate, extending the life expectancy of patients.
Biostock Highlights Neola Medicals Q3 2022 Oct 11, 2022 2022 cell & gene meeting on the mesa, carlsbad, october 11 13 – oct 6, 2022 icrs focus meeting, bologna, october 6 7 – sep 28, 2022 nordic life science days, malmö, september 28 29, 2022 – aug 30, 2022 2nd integrin targeted drug development summit, boston, august 30 september 1 – jun 13, 2022 småbolagsdagarna, stockholm. We proudly welcome you to the 5th annual fall edition of the biostock life science summit at medicon village in lund on november 29 30! this year, we will meet in person, as around 30 listed and private companies from a wide range of therapeutic areas present their innovations and business cases to invited investors. Lund based neola medical can look back on an eventful period when reporting the third quarter of 2022. positive study results and a successful capital raise provide a stable foundation for the future, where the focus will be on the regulatory work ahead of the market launch. Patients receiving the combination therapy demonstrated a higher tumor response rate and longer progression free survival compared to those receiving chemotherapy alone. moreover, the combination therapy also led to a promising overall survival rate, extending the life expectancy of patients.
Comments are closed.